Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

← catalyst calendar

NCT04379596 · readout in 286 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

450estimated

Sites

100

Countries

Brazil, Canada, China +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-06-03

actual

When the study began enrolling

Primary completion

2027-06-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-06-01

estimated

The whole study's end, after follow-up

First posted

2020-05-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Gastric Cancer

Interventions

Drug: Fluorouracil (5-FU)
Drug: Capecitabine
Biological: Durvalumab — also filed as MEDI4736
Drug: Oxaliplatin
Biological: Trastuzumab
Drug: Trastuzumab deruxtecan — also filed as DS-8201a, Enhertu
Drug: Cisplatin
Biological: Pembrolizumab
Biological: Volrustomig — also filed as MEDI5752
Biological: Rilvegostomig — also filed as AZD2936

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0